138 related articles for article (PubMed ID: 21536930)
1. Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer.
Okudaira H; Shikano N; Nishii R; Miyagi T; Yoshimoto M; Kobayashi M; Ohe K; Nakanishi T; Tamai I; Namiki M; Kawai K
J Nucl Med; 2011 May; 52(5):822-9. PubMed ID: 21536930
[TBL] [Abstract][Full Text] [Related]
2. PET imaging of hepatocellular carcinoma with anti-1-amino-3-[
Sergeeva O; Zhang Y; Kenyon JD; Miller-Atkins GA; Wu C; Iyer R; Sexton S; Wojtylak P; Awadallah A; Xin W; Chan ER; O'Donnel JK; Lee Z
EJNMMI Res; 2019 May; 9(1):47. PubMed ID: 31119488
[TBL] [Abstract][Full Text] [Related]
3. 18F-Fluciclovine Uptake in Thymoma Demonstrated on PET/MRI.
Tsikitas L; Karls S; Kranz AO; Friedman KP; Mahajan S
Clin Nucl Med; 2021 Mar; 46(3):e168-e170. PubMed ID: 32956127
[TBL] [Abstract][Full Text] [Related]
4. 18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy.
Malviya G; Patel R; Salji M; Martinez RS; Repiscak P; Mui E; Champion S; Mrowinska A; Johnson E; AlRasheedi M; Pimlott S; Lewis D; Leung HY
EJNMMI Res; 2020 Nov; 10(1):143. PubMed ID: 33237350
[TBL] [Abstract][Full Text] [Related]
5. A one-gate elevator mechanism for the human neutral amino acid transporter ASCT2.
Garaeva AA; Guskov A; Slotboom DJ; Paulino C
Nat Commun; 2019 Jul; 10(1):3427. PubMed ID: 31366933
[TBL] [Abstract][Full Text] [Related]
6. Discovery and Synthesis of Hydroxy-l-Proline Blockers of the Neutral Amino Acid Transporters SLC1A4 (ASCT1) and SLC1A5 (ASCT2).
Lyda BR; Leary GP; Farnsworth J; Seaver B; Silvius D; Kavanaugh MP; Esslinger CS; Natale NR
Molecules; 2024 May; 29(10):. PubMed ID: 38792190
[TBL] [Abstract][Full Text] [Related]
7. A multi-hierarchical approach reveals d-serine as a hidden substrate of sodium-coupled monocarboxylate transporters.
Wiriyasermkul P; Moriyama S; Suzuki M; Kongpracha P; Nakamae N; Takeshita S; Tanaka Y; Matsuda A; Miyasaka M; Hamase K; Kimura T; Mita M; Sasabe J; Nagamori S
Elife; 2024 Apr; 12():. PubMed ID: 38650461
[TBL] [Abstract][Full Text] [Related]
8. A conserved Na(+) binding site of the sodium-coupled neutral amino acid transporter 2 (SNAT2).
Zhang Z; Albers T; Fiumera HL; Gameiro A; Grewer C
J Biol Chem; 2009 Sep; 284(37):25314-23. PubMed ID: 19589777
[TBL] [Abstract][Full Text] [Related]
9. L-Cysteine-mediated modulation of copper trafficking in prostate cancer cells: an
Bartnicka JJ; Al-Salemee F; Firth G; Blower PJ
Metallomics; 2020 Oct; 12(10):1508-1520. PubMed ID: 32959856
[TBL] [Abstract][Full Text] [Related]
10. Initial evaluation of [
Morath V; Heider M; Mittelhäuser M; Rolbieski H; Stroh J; Calais J; Eiber M; Bassermann F; Weber WA
EJNMMI Res; 2022 Jan; 12(1):4. PubMed ID: 35099620
[TBL] [Abstract][Full Text] [Related]
11. Transient kinetics reveal the mechanism of competitive inhibition of the neutral amino acid transporter ASCT2.
Dong Y; Wang J; Grewer C
J Biol Chem; 2024 May; 300(6):107382. PubMed ID: 38763337
[TBL] [Abstract][Full Text] [Related]
12. A GC-MS/Single-Cell Method to Evaluate Membrane Transporter Substrate Specificity and Signaling.
Fairweather SJ; Okada S; Gauthier-Coles G; Javed K; Bröer A; Bröer S
Front Mol Biosci; 2021; 8():646574. PubMed ID: 33928121
[TBL] [Abstract][Full Text] [Related]
13. Alanine serine cysteine transporter (ASCT) substrate binding site properties probed with hydroxyhomoserine esters.
Ndaru E; Zielewicz L; Shi Y; Hutchinson K; Garibsingh RA; Schlessinger A; Grewer C
J Phys Org Chem; 2022 Nov; 35(11):. PubMed ID: 36568026
[TBL] [Abstract][Full Text] [Related]
14. Exploring Amino Acid Transporters as Therapeutic Targets for Cancer: An Examination of Inhibitor Structures, Selectivity Issues, and Discovery Approaches.
Jakobsen S; Nielsen CU
Pharmaceutics; 2024 Jan; 16(2):. PubMed ID: 38399253
[TBL] [Abstract][Full Text] [Related]
15. Investigations of potential non-amino acid SNAT2 inhibitors.
Jakobsen S; Petersen EF; Nielsen CU
Front Pharmacol; 2023; 14():1302445. PubMed ID: 38239202
[TBL] [Abstract][Full Text] [Related]
16. Retraction: Specific expression of lncRNA RP13-650J16.1 and TCONS_00023979 in prostate cancer.
Biosci Rep; 2024 Feb; 44(2):. PubMed ID: 38345104
[No Abstract] [Full Text] [Related]
17. Kinetic analyses of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2.
Okudaira H; Nakanishi T; Oka S; Kobayashi M; Tamagami H; Schuster DM; Goodman MM; Shirakami Y; Tamai I; Kawai K
Nucl Med Biol; 2013 Jul; 40(5):670-5. PubMed ID: 23647854
[TBL] [Abstract][Full Text] [Related]
18. Differences in transport mechanisms of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid in inflammation, prostate cancer, and glioma cells: comparison with L-[methyl-11C]methionine and 2-deoxy-2-[18F]fluoro-D-glucose.
Oka S; Okudaira H; Ono M; Schuster DM; Goodman MM; Kawai K; Shirakami Y
Mol Imaging Biol; 2014 Jun; 16(3):322-9. PubMed ID: 24136390
[TBL] [Abstract][Full Text] [Related]
19. Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature.
Yu CY; Desai B; Ji L; Groshen S; Jadvar H
Am J Nucl Med Mol Imaging; 2014; 4(6):580-601. PubMed ID: 25250207
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters.
Okudaira H; Oka S; Ono M; Nakanishi T; Schuster DM; Kobayashi M; Goodman MM; Tamai I; Kawai K; Shirakami Y
Mol Imaging Biol; 2014 Dec; 16(6):756-64. PubMed ID: 24943499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
